N R Tavares1, P A Moreira, T F Amaral. 1. Faculdade de Ciências da Nutrição e Alimentação da Universidade do Porto, Porto, Portugal.
Abstract
BACKGROUND: High levels of total plasma homocysteine are potentially harmful in the elderly. OBJECTIVE: To investigated the effects of oral riboflavin supplementation on plasma total homocysteine, ferritin, uric acid and C-reactive protein concentration in elderly people with a low riboflavin status. We performed a four-week randomized, placebo-controlled, double-blind trial of riboflavin supplementation in seven Portuguese day social centers. DESIGN:Eighty-eight individuals (66.7% female), aged between 60 and 94 years, volunteered to participate in the study following interview. Forty-two subjects, with an erythrocyte glutathione reductase activation coefficient (EGRAC) >or= 1.2, were included in the intervention trial. All subjects gave informed consent. Study subjects were administered 10 mg riboflavin (n=21) or placebo (n=21) each day for 28 days. RESULTS:Riboflavin supplementation significantly decreased plasma tHcy (P=0.005) and EGRAC (P=0.014), but not plasma ferritin, uric acid or C-reactive protein. CONCLUSIONS: In this elderly group, we found that 10 mg/day oral riboflavin supplementation lowered plasma homocysteine concentrations in subjects with low riboflavin status.
RCT Entities:
BACKGROUND: High levels of total plasma homocysteine are potentially harmful in the elderly. OBJECTIVE: To investigated the effects of oral riboflavin supplementation on plasma total homocysteine, ferritin, uric acid and C-reactive protein concentration in elderly people with a low riboflavin status. We performed a four-week randomized, placebo-controlled, double-blind trial of riboflavin supplementation in seven Portuguese day social centers. DESIGN: Eighty-eight individuals (66.7% female), aged between 60 and 94 years, volunteered to participate in the study following interview. Forty-two subjects, with an erythrocyte glutathione reductase activation coefficient (EGRAC) >or= 1.2, were included in the intervention trial. All subjects gave informed consent. Study subjects were administered 10 mg riboflavin (n=21) or placebo (n=21) each day for 28 days. RESULTS:Riboflavin supplementation significantly decreased plasma tHcy (P=0.005) and EGRAC (P=0.014), but not plasma ferritin, uric acid or C-reactive protein. CONCLUSIONS: In this elderly group, we found that 10 mg/day oral riboflavin supplementation lowered plasma homocysteine concentrations in subjects with low riboflavin status.
Authors: K Klipstein-Grobusch; J F Koster; D E Grobbee; J Lindemans; H Boeing; A Hofman; J C Witteman Journal: Am J Clin Nutr Date: 1999-06 Impact factor: 7.045
Authors: R A Akasov; E V Khaydukov; D S Andreyuk; N V Sholina; A N Sheremeta; D V Romanov; G P Kostyuk; V Ya Panchenko; M V Kovalchuk Journal: Front Pharmacol Date: 2022-03-10 Impact factor: 5.810